Ligand Pharmaceuticals Incorporated (LGND)
USD 99.8
(-3.21%)
USD 99.8
(-3.21%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 5.75 Million USD | -44.32% |
| 2022 | 10.33 Million USD | -96.93% |
| 2021 | 336.21 Million USD | -24.94% |
| 2020 | 447.93 Million USD | -30.97% |
| 2019 | 648.92 Million USD | 6.41% |
| 2018 | 609.86 Million USD | 3133.81% |
| 2017 | 18.85 Million USD | -36.21% |
| 2016 | 29.56 Million USD | -85.61% |
| 2015 | 205.37 Million USD | 4.83% |
| 2014 | 195.9 Million USD | 6279.29% |
| 2013 | 3.07 Million USD | -77.16% |
| 2012 | 13.44 Million USD | -62.18% |
| 2011 | 35.54 Million USD | 55.53% |
| 2010 | 22.85 Million USD | -26.27% |
| 2009 | 30.99 Million USD | 1323.0% |
| 2008 | 2.17 Million USD | 247.37% |
| 2007 | 627 Thousand USD | -70.92% |
| 2006 | 2.15 Million USD | -98.73% |
| 2005 | 170.17 Million USD | -0.54% |
| 2004 | 171.09 Million USD | 0.61% |
| 2003 | 170.05 Million USD | 9.53% |
| 2002 | 155.25 Million USD | 13.52% |
| 2001 | 136.75 Million USD | 3.84% |
| 2000 | 131.7 Million USD | -3.65% |
| 1999 | 136.7 Million USD | 51.05% |
| 1998 | 90.5 Million USD | 76.07% |
| 1997 | 51.4 Million USD | -4.81% |
| 1996 | 54 Million USD | 8.22% |
| 1995 | 49.9 Million USD | 305.69% |
| 1994 | 12.3 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 5.19 Million USD | 0.0% |
| 2024 Q2 | 6.41 Million USD | 0.0% |
| 2023 Q1 | 11.18 Million USD | 8.19% |
| 2023 Q3 | 5.83 Million USD | -46.94% |
| 2023 Q4 | 5.75 Million USD | -1.32% |
| 2023 FY | 5.75 Million USD | -44.32% |
| 2023 Q2 | 10.99 Million USD | -1.72% |
| 2022 FY | 10.33 Million USD | -96.93% |
| 2022 Q2 | 27.08 Million USD | -84.66% |
| 2022 Q1 | 176.54 Million USD | -47.49% |
| 2022 Q4 | 10.33 Million USD | -70.38% |
| 2022 Q3 | 34.89 Million USD | 28.81% |
| 2021 FY | 336.21 Million USD | -24.94% |
| 2021 Q1 | 352.31 Million USD | -21.35% |
| 2021 Q2 | 315.31 Million USD | -10.5% |
| 2021 Q3 | 328.35 Million USD | 4.13% |
| 2021 Q4 | 336.21 Million USD | 2.39% |
| 2020 Q4 | 447.93 Million USD | -1.55% |
| 2020 Q3 | 454.97 Million USD | 1.18% |
| 2020 Q2 | 449.67 Million USD | 1.18% |
| 2020 Q1 | 444.43 Million USD | -31.51% |
| 2020 FY | 447.93 Million USD | -30.97% |
| 2019 FY | 648.92 Million USD | 6.41% |
| 2019 Q2 | 624.2 Million USD | 1.17% |
| 2019 Q3 | 631.53 Million USD | 1.17% |
| 2019 Q4 | 648.92 Million USD | 2.75% |
| 2019 Q1 | 616.98 Million USD | 1.17% |
| 2018 Q3 | 602.83 Million USD | 1.16% |
| 2018 FY | 609.86 Million USD | 3133.81% |
| 2018 Q4 | 609.86 Million USD | 1.17% |
| 2018 Q2 | 595.91 Million USD | 3606.38% |
| 2018 Q1 | 16.07 Million USD | -14.75% |
| 2017 Q2 | 24.29 Million USD | -9.85% |
| 2017 Q1 | 26.94 Million USD | -8.85% |
| 2017 FY | 18.85 Million USD | -36.21% |
| 2017 Q4 | 18.85 Million USD | -12.68% |
| 2017 Q3 | 21.59 Million USD | -11.1% |
| 2016 Q3 | 32.13 Million USD | -86.72% |
| 2016 Q1 | 204.65 Million USD | -0.35% |
| 2016 Q4 | 29.56 Million USD | -8.01% |
| 2016 FY | 29.56 Million USD | -85.61% |
| 2016 Q2 | 242.03 Million USD | 18.27% |
| 2015 Q1 | 198.21 Million USD | 1.18% |
| 2015 Q3 | 202.95 Million USD | 1.19% |
| 2015 FY | 205.37 Million USD | 4.83% |
| 2015 Q2 | 200.56 Million USD | 1.18% |
| 2015 Q4 | 205.37 Million USD | 1.19% |
| 2014 Q2 | 1.58 Million USD | -32.15% |
| 2014 Q3 | 193.63 Million USD | 12101.07% |
| 2014 Q4 | 195.9 Million USD | 1.18% |
| 2014 FY | 195.9 Million USD | 6279.29% |
| 2014 Q1 | 2.33 Million USD | -23.84% |
| 2013 Q2 | 1.97 Million USD | -64.14% |
| 2013 Q3 | 3.72 Million USD | 89.09% |
| 2013 Q1 | 5.49 Million USD | -59.13% |
| 2013 Q4 | 3.07 Million USD | -17.56% |
| 2013 FY | 3.07 Million USD | -77.16% |
| 2012 Q2 | 22.21 Million USD | -15.98% |
| 2012 Q3 | 24.41 Million USD | 9.9% |
| 2012 Q4 | 13.44 Million USD | -44.93% |
| 2012 FY | 13.44 Million USD | -62.18% |
| 2012 Q1 | 26.43 Million USD | 30.31% |
| 2011 FY | 35.54 Million USD | 55.53% |
| 2011 Q2 | 29.97 Million USD | -1.97% |
| 2011 Q1 | 30.57 Million USD | 33.81% |
| 2011 Q4 | 20.28 Million USD | -59.42% |
| 2011 Q3 | 49.98 Million USD | 66.76% |
| 2010 Q4 | 22.85 Million USD | -20.15% |
| 2010 Q3 | 28.61 Million USD | -2.61% |
| 2010 Q2 | 29.38 Million USD | -14.43% |
| 2010 Q1 | 34.34 Million USD | -5.33% |
| 2010 FY | 22.85 Million USD | -26.27% |
| 2009 Q4 | 36.27 Million USD | -20.06% |
| 2009 Q1 | 46.86 Million USD | 2051.52% |
| 2009 Q2 | 46.17 Million USD | -1.47% |
| 2009 Q3 | 45.37 Million USD | -1.73% |
| 2009 FY | 30.99 Million USD | 1323.0% |
| 2008 FY | 2.17 Million USD | 247.37% |
| 2008 Q1 | 403 Thousand USD | -35.73% |
| 2008 Q2 | 266 Thousand USD | -34.0% |
| 2008 Q3 | 172 Thousand USD | -35.34% |
| 2008 Q4 | 2.17 Million USD | 1166.28% |
| 2007 FY | 627 Thousand USD | -70.92% |
| 2007 Q1 | 1.64 Million USD | -23.89% |
| 2007 Q2 | 1.25 Million USD | -23.28% |
| 2007 Q3 | 889 Thousand USD | -29.39% |
| 2007 Q4 | 627 Thousand USD | -29.47% |
| 2006 Q3 | 142.07 Million USD | -0.17% |
| 2006 Q4 | 2.15 Million USD | -98.48% |
| 2006 Q1 | 143.8 Million USD | -15.5% |
| 2006 Q2 | 142.31 Million USD | -1.04% |
| 2006 FY | 2.15 Million USD | -98.73% |
| 2005 Q1 | 171.11 Million USD | 0.01% |
| 2005 FY | 170.17 Million USD | -0.54% |
| 2005 Q2 | 170.82 Million USD | -0.17% |
| 2005 Q3 | 170.19 Million USD | -0.37% |
| 2005 Q4 | 170.17 Million USD | -0.01% |
| 2004 FY | 171.09 Million USD | 0.61% |
| 2004 Q4 | 171.09 Million USD | -0.1% |
| 2004 Q3 | 171.25 Million USD | 2.39% |
| 2004 Q2 | 167.25 Million USD | -2.1% |
| 2004 Q1 | 170.84 Million USD | 0.47% |
| 2003 Q1 | 155.25 Million USD | 0.0% |
| 2003 Q3 | 155.25 Million USD | -2.14% |
| 2003 Q2 | 158.65 Million USD | 2.19% |
| 2003 FY | 170.05 Million USD | 9.53% |
| 2003 Q4 | 170.05 Million USD | 9.53% |
| 2002 Q1 | 2.87 Million USD | -97.89% |
| 2002 FY | 155.25 Million USD | 13.52% |
| 2002 Q3 | 7.05 Million USD | 167.08% |
| 2002 Q4 | 155.25 Million USD | 2101.82% |
| 2002 Q2 | 2.64 Million USD | -8.3% |
| 2001 FY | 136.75 Million USD | 3.84% |
| 2001 Q2 | 142.17 Million USD | 6.62% |
| 2001 Q3 | 137.06 Million USD | -3.6% |
| 2001 Q4 | 136.75 Million USD | -0.22% |
| 2001 Q1 | 133.34 Million USD | 1.24% |
| 2000 FY | 131.7 Million USD | -3.65% |
| 2000 Q3 | 120.19 Million USD | 1.24% |
| 2000 Q1 | 117.1 Million USD | -14.33% |
| 2000 Q2 | 118.72 Million USD | 1.38% |
| 2000 Q4 | 131.7 Million USD | 9.58% |
| 1999 Q4 | 136.7 Million USD | -11.58% |
| 1999 Q2 | 92.8 Million USD | 1.87% |
| 1999 Q1 | 91.1 Million USD | 0.66% |
| 1999 FY | 136.7 Million USD | 51.05% |
| 1999 Q3 | 154.6 Million USD | 66.59% |
| 1998 Q3 | 49.7 Million USD | 1.64% |
| 1998 Q1 | 52.1 Million USD | 1.36% |
| 1998 FY | 90.5 Million USD | 76.07% |
| 1998 Q4 | 90.5 Million USD | 82.09% |
| 1998 Q2 | 48.9 Million USD | -6.14% |
| 1997 Q3 | 49.7 Million USD | -3.5% |
| 1997 FY | 51.4 Million USD | -4.81% |
| 1997 Q4 | 51.4 Million USD | 3.42% |
| 1997 Q2 | 51.5 Million USD | 1.38% |
| 1997 Q1 | 50.8 Million USD | -5.93% |
| 1996 Q2 | 51.3 Million USD | 1.38% |
| 1996 Q4 | 54 Million USD | 12.27% |
| 1996 Q1 | 50.6 Million USD | 1.4% |
| 1996 Q3 | 48.1 Million USD | -6.24% |
| 1996 FY | 54 Million USD | 8.22% |
| 1995 FY | 49.9 Million USD | 305.69% |
| 1995 Q3 | 49.6 Million USD | 0.0% |
| 1995 Q1 | 12 Million USD | -2.44% |
| 1995 Q4 | 49.9 Million USD | 0.6% |
| 1994 Q4 | 12.3 Million USD | 0.0% |
| 1994 Q2 | 2.3 Million USD | 0.0% |
| 1994 Q3 | 12.3 Million USD | 434.78% |
| 1994 FY | 12.3 Million USD | 0.0% |
| 1994 Q1 | 2.3 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | 71.22 Million USD | 91.92% |
| Alkermes plc | 287.73 Million USD | 98.0% |
| Agenus Inc. | 137.32 Million USD | 95.809% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 99.754% |
| Aptorum Group Limited | 3.05 Million USD | -88.164% |
| Ardelyx, Inc. | 51.54 Million USD | 88.835% |
| Arrowhead Pharmaceuticals, Inc. | 104.6 Million USD | 94.499% |
| Bicycle Therapeutics plc | 40.08 Million USD | 85.641% |
| BioXcel Therapeutics, Inc. | 100.59 Million USD | 94.279% |
| ChromaDex Corporation | 2.57 Million USD | -123.495% |
| Chimerix, Inc. | 125 Thousand USD | -4504.0% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -77.699% |
| Caribou Biosciences, Inc. | 25.9 Million USD | 77.787% |
| CRISPR Therapeutics AG | 223 Million USD | 97.419% |
| Precision BioSciences, Inc. | 7.72 Million USD | 25.482% |
| Dyadic International, Inc. | 88.87 Thousand USD | -6375.751% |
| Eton Pharmaceuticals, Inc. | 22 Thousand USD | -26059.091% |
| Fortress Biotech, Inc. | 60.85 Million USD | 90.543% |
| Lantern Pharma Inc. | 61.49 Thousand USD | -9258.332% |
| HOOKIPA Pharma Inc. | 3.8 Million USD | -51.408% |
| Inhibikase Therapeutics, Inc. | 90.12 Thousand USD | -6285.646% |
| Incyte Corporation | 29.16 Million USD | 80.265% |
| IO Biotech, Inc. | 1.83 Million USD | -212.942% |
| Jaguar Health, Inc. | 30.99 Million USD | 81.431% |
| Novavax, Inc. | 168.01 Million USD | 96.575% |
| Janux Therapeutics, Inc. | 23.02 Million USD | 75.005% |
| Opthea Limited | 200.53 Million USD | 97.13% |
| ContextLogic Inc. | 6 Million USD | 4.083% |
| MiMedx Group, Inc. | 48.09 Million USD | 88.035% |
| Pyxis Oncology, Inc. | 20.09 Million USD | 71.367% |
| TransCode Therapeutics, Inc. | 38.29 Thousand USD | -14929.641% |
| NextCure, Inc. | 5.94 Million USD | 3.261% |
| Ocuphire Pharma, Inc. | - USD | -Infinity% |
| Oncternal Therapeutics, Inc. | 145 Thousand USD | -3868.966% |
| Outlook Therapeutics, Inc. | - USD | -Infinity% |
| Vaxcyte, Inc. | 22.11 Million USD | 73.972% |
| PDS Biotechnology Corporation | 19.5 Million USD | 70.497% |
| Madrigal Pharmaceuticals, Inc. | 115.48 Million USD | 95.016% |
| Pharming Group N.V. | 166.1 Million USD | 96.535% |
| Pieris Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avidity Biosciences, Inc. | 6.21 Million USD | 7.372% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 82.829% |
| Sol-Gel Technologies Ltd. | 1.2 Million USD | -377.197% |
| Acelyrin, Inc. | 1.19 Million USD | -381.993% |
| Salarius Pharmaceuticals, Inc. | - USD | -Infinity% |
| SELLAS Life Sciences Group, Inc. | 460 Thousand USD | -1151.087% |
| Summit Therapeutics Inc. | 103.29 Million USD | 94.428% |
| Sensei Biotherapeutics, Inc. | 3.76 Million USD | -52.693% |
| Senti Biosciences, Inc. | 33.53 Million USD | 82.84% |
| Stoke Therapeutics, Inc. | 4.77 Million USD | -20.574% |
| Syros Pharmaceuticals, Inc. | 34.55 Million USD | 83.346% |
| Alaunos Therapeutics, Inc. | - USD | -Infinity% |
| Telomir Pharmaceuticals, Inc. Common Stock | - USD | -Infinity% |
| Entrada Therapeutics, Inc. | 60.32 Million USD | 90.459% |
| VistaGen Therapeutics, Inc. | 1.57 Million USD | -266.561% |
| Wave Life Sciences Ltd. | 25.4 Million USD | 77.346% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 94.484% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -686.202% |
| Barinthus Biotherapeutics plc | 11.19 Million USD | 48.575% |
| Psyence Biomedical Ltd. | - USD | -Infinity% |
| Phathom Pharmaceuticals, Inc. | 138.3 Million USD | 95.839% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| Keros Therapeutics, Inc. | 13.43 Million USD | 57.177% |
| MEI Pharma, Inc. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 15 Million USD | 61.633% |
| Xeris Biopharma Holdings, Inc. | 190.93 Million USD | 96.986% |
| Rigel Pharmaceuticals, Inc. | 52.65 Million USD | 89.071% |
| Fortress Biotech, Inc. | 60.85 Million USD | 90.543% |
| Precigen, Inc. | 5.89 Million USD | 2.375% |
| Clearside Biomedical, Inc. | 41.98 Million USD | 86.294% |
| AlloVir, Inc. | 16.64 Million USD | 65.431% |
| C4 Therapeutics, Inc. | 65.75 Million USD | 91.248% |
| Fate Therapeutics, Inc. | 97.36 Million USD | 94.089% |
| ImmuCell Corporation | 10.54 Million USD | 45.401% |
| IDEAYA Biosciences, Inc. | 1.12 Million USD | -411.556% |
| Onconetix, Inc. | 118.85 Thousand USD | -4741.953% |
| PureTech Health plc | 18.25 Million USD | 68.466% |
| VYNE Therapeutics Inc. | 99 Thousand USD | -5713.131% |
| Elevation Oncology, Inc. | 30.13 Million USD | 80.904% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| Seer, Inc. | 25.96 Million USD | 77.835% |
| Verrica Pharmaceuticals Inc. | 42.87 Million USD | 86.577% |
| Innoviva, Inc. | 446.23 Million USD | 98.71% |
| Aadi Bioscience, Inc. | 833 Thousand USD | -590.876% |
| ESSA Pharma Inc. | - USD | -Infinity% |
| GlycoMimetics, Inc. | 66.84 Thousand USD | -8509.598% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Inhibrx Biosciences, Inc. | 206.96 Million USD | 97.219% |
| Akebia Therapeutics, Inc. | 71.19 Million USD | 91.917% |
| Catalyst Pharmaceuticals, Inc. | 3.18 Million USD | -80.521% |
| Longboard Pharmaceuticals, Inc. | - USD | -Infinity% |
| Orchestra BioMed Holdings, Inc. | 1.03 Million USD | -454.432% |
| Alzamend Neuro, Inc. | - USD | -Infinity% |
| Rocket Pharmaceuticals, Inc. | 22.32 Million USD | 74.223% |
| Aptose Biosciences Inc. | 621 Thousand USD | -826.731% |
| ZyVersa Therapeutics, Inc. | - USD | -Infinity% |
| Soligenix, Inc. | 1.01 Million USD | -469.276% |
| Century Therapeutics, Inc. | 46.65 Million USD | 87.666% |
| Kura Oncology, Inc. | 9.33 Million USD | 38.33% |
| TScan Therapeutics, Inc. | 26.7 Million USD | 78.446% |
| Intensity Therapeutics, Inc. | 138 Thousand USD | -4070.29% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 9.38 Million USD | 38.679% |
| Autolus Therapeutics plc | 47.91 Million USD | 87.989% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 4.9 Million USD | -17.305% |
| Eterna Therapeutics Inc. | 6.77 Million USD | 15.03% |
| Adaptive Biotechnologies Corporation | 130.66 Million USD | 95.595% |
| GRI Bio, Inc. | - USD | -Infinity% |
| Xenetic Biosciences, Inc. | - USD | -Infinity% |
| Tenaya Therapeutics, Inc. | 8.1 Million USD | 28.994% |
| IGM Biosciences, Inc. | 34.67 Million USD | 83.402% |
| INmune Bio, Inc. | 397 Thousand USD | -1349.622% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 96.688% |
| SAB Biotherapeutics, Inc. | 4.05 Million USD | -41.949% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Entero Therapeutics, Inc. | 146.94 Thousand USD | -3816.325% |
| Milestone Pharmaceuticals Inc. | 49.77 Million USD | 88.437% |
| X4 Pharmaceuticals, Inc. | 54.57 Million USD | 89.454% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 87.405% |
| Coherus BioSciences, Inc. | 473.36 Million USD | 98.784% |
| Verastem, Inc. | 40.08 Million USD | 85.643% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -30.736% |
| Pliant Therapeutics, Inc. | 10.05 Million USD | 42.759% |
| Tonix Pharmaceuticals Holding Corp. | 6.56 Million USD | 12.285% |
| Histogen Inc. | 4.38 Million USD | -31.273% |
| Aprea Therapeutics, Inc. | - USD | -Infinity% |
| Surrozen, Inc. | 882 Thousand USD | -552.494% |
| Organovo Holdings, Inc. | 888 Thousand USD | -548.086% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | 30 Million USD | 80.817% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | -37.22% |
| CASI Pharmaceuticals, Inc. | 18.89 Million USD | 69.542% |
| Cadrenal Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Centessa Pharmaceuticals plc | 75.7 Million USD | 92.398% |
| Hepion Pharmaceuticals, Inc. | 93.1 Thousand USD | -6081.26% |
| Arcturus Therapeutics Holdings Inc. | 25.9 Million USD | 77.786% |
| BioRestorative Therapies, Inc. | - USD | -Infinity% |
| Apollomics, Inc. | 267 Thousand USD | -2055.431% |
| Amarin Corporation plc | 8.73 Million USD | 34.131% |
| Mesoblast Limited | 100.48 Million USD | 94.273% |
| Turnstone Biologics Corp. | 1.18 Million USD | -384.02% |
| Kymera Therapeutics, Inc. | 78.32 Million USD | 92.653% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | 109 Thousand USD | -5179.817% |
| Aurinia Pharmaceuticals Inc. | 82 Million USD | 92.982% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 189.94 Million USD | 96.97% |
| Better Therapeutics, Inc. | 10.34 Million USD | 44.385% |
| Nurix Therapeutics, Inc. | 23.12 Million USD | 75.114% |
| Apellis Pharmaceuticals, Inc. | 93.03 Million USD | 93.814% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | -345.433% |
| Gritstone bio, Inc. | 40.14 Million USD | 85.664% |
| Jasper Therapeutics, Inc. | 1.81 Million USD | -217.255% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 153.59 Million USD | 96.253% |
| Insmed Incorporated | 1.19 Billion USD | 99.518% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 6.35 Million USD | 9.37% |
| OmniAb, Inc. | 22.07 Million USD | 73.93% |
| Alector, Inc. | 30.45 Million USD | 81.104% |
| Seres Therapeutics, Inc. | 101.54 Million USD | 94.333% |
| Checkpoint Therapeutics, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| Zai Lab Limited | 8.04 Million USD | 28.483% |
| Revance Therapeutics, Inc. | 426.59 Million USD | 98.651% |
| Aura Biosciences, Inc. | 16.87 Million USD | 65.886% |
| Lyell Immunopharma, Inc. | 56.89 Million USD | 89.885% |
| Immunic, Inc. | 639 Thousand USD | -800.626% |
| Tarsus Pharmaceuticals, Inc. | 29.81 Million USD | 80.7% |
| Veracyte, Inc. | 7.52 Million USD | 23.522% |
| InMed Pharmaceuticals Inc. | 644.86 Million USD | 99.108% |
| FibroGen, Inc. | 89.69 Million USD | 93.584% |
| SeaStar Medical Holding Corporation | 4.33 Million USD | -32.695% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 130.86 Thousand USD | -4297.729% |
| Jazz Pharmaceuticals plc | 5.1 Billion USD | 99.887% |
| Cyclacel Pharmaceuticals, Inc. | 37 Thousand USD | -15454.054% |
| Amylyx Pharmaceuticals, Inc. | 1.98 Million USD | -190.657% |
| TG Therapeutics, Inc. | 100.11 Million USD | 94.252% |
| Galecto, Inc. | 66 Thousand USD | -8619.697% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -4131.618% |
| Fortrea Holdings Inc. | 1.63 Billion USD | 99.647% |
| KalVista Pharmaceuticals, Inc. | 6.01 Million USD | 4.323% |
| Aptevo Therapeutics Inc. | 5.39 Million USD | -6.633% |
| XBiotech Inc. | - USD | -Infinity% |
| Jasper Therapeutics, Inc. | 1.81 Million USD | -217.255% |
| Lyra Therapeutics, Inc. | 21.44 Million USD | 73.166% |
| Foghorn Therapeutics Inc. | 36.55 Million USD | 84.257% |
| Y-mAbs Therapeutics, Inc. | 517 Thousand USD | -1013.153% |
| Theravance Biopharma, Inc. | 45.23 Million USD | 87.278% |
| Ultragenyx Pharmaceutical Inc. | 30.57 Million USD | 81.177% |
| Metagenomi, Inc. Common Stock | 44.8 Million USD | 87.155% |
| Vaxxinity, Inc. | 13.26 Million USD | 56.605% |
| BioCryst Pharmaceuticals, Inc. | 811.26 Million USD | 99.291% |
| Gain Therapeutics, Inc. | 449.05 Thousand USD | -1181.586% |
| Cartesian Therapeutics, Inc. | 8.78 Million USD | 34.52% |
| NexImmune, Inc. | - USD | -Infinity% |
| Creative Medical Technology Holdings, Inc. | - USD | -Infinity% |
| Marker Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.787% |
| Chemomab Therapeutics Ltd. | 316 Thousand USD | -1721.203% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | 4.45 Million USD | -29.094% |
| Ainos, Inc. | 5.92 Million USD | 2.813% |
| Pluri Inc. | 29.05 Million USD | 80.191% |
| Prothena Corporation plc | 10.72 Million USD | 46.32% |
| Adaptimmune Therapeutics plc | 19.85 Million USD | 71.009% |
| Celularity Inc. | 26.17 Million USD | 78.015% |
| Rallybio Corporation | 173 Thousand USD | -3226.59% |
| Cue Biopharma, Inc. | 4.2 Million USD | -36.959% |
| MeiraGTx Holdings plc | 72.11 Million USD | 92.02% |
| Omeros Corporation | 329.7 Million USD | 98.255% |
| Humacyte, Inc. | 38.6 Million USD | 85.091% |
| Immunocore Holdings plc | 82.64 Million USD | 93.036% |
| Cocrystal Pharma, Inc. | 1.61 Million USD | -256.789% |
| Cidara Therapeutics, Inc. | 3.57 Million USD | -60.889% |
| Blueprint Medicines Corporation | 610.96 Million USD | 99.058% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | 1.45 Million USD | -294.719% |
| Marinus Pharmaceuticals, Inc. | 95.18 Million USD | 93.954% |
| Scholar Rock Holding Corporation | 48.68 Million USD | 88.179% |
| Sana Biotechnology, Inc. | 90.9 Million USD | 93.669% |
| Pulmatrix, Inc. | 8.32 Million USD | 30.887% |
| Elicio Therapeutics, Inc. | 6 Million USD | 4.195% |
| Vigil Neuroscience, Inc. | 12.94 Million USD | 55.543% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 94.051% |
| Adlai Nortye Ltd. American Depositary Shares | 469 Thousand USD | -1127.079% |
| Cytokinetics, Incorporated | 607.37 Million USD | 99.052% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | 33.79% |
| Nutriband Inc. | 79.82 Thousand USD | -7109.431% |
| Protara Therapeutics, Inc. | 4.48 Million USD | -28.345% |
| Vor Biopharma Inc. | 31.83 Million USD | 81.92% |
| Roivant Sciences Ltd. | 477.85 Million USD | 98.796% |
| Evogene Ltd. | 10.65 Million USD | 45.978% |
| ProKidney Corp. | 3.61 Million USD | -59.418% |
| Applied Therapeutics, Inc. | 759 Thousand USD | -658.235% |
| Hoth Therapeutics, Inc. | 26.32 Thousand USD | -21760.518% |
| BridgeBio Pharma, Inc. | 1.73 Billion USD | 99.668% |
| CorMedix Inc. | 517.01 Thousand USD | -1013.125% |
| BioLineRx Ltd. | 6.62 Million USD | 13.171% |
| Tango Therapeutics, Inc. | 36.83 Million USD | 84.378% |
| Galectin Therapeutics Inc. | 71.74 Million USD | 91.978% |
| Atai Life Sciences N.V. | 15.21 Million USD | 62.166% |
| Renovaro Biosciences Inc. | 842.38 Thousand USD | -583.176% |
| Aerovate Therapeutics, Inc. | 255 Thousand USD | -2156.863% |
| Zentalis Pharmaceuticals, Inc. | 43.15 Million USD | 86.663% |
| Sagimet Biosciences Inc. | - USD | -Infinity% |
| MediciNova, Inc. | 410.66 Thousand USD | -1301.403% |
| Praxis Precision Medicines, Inc. | 1.36 Million USD | -320.38% |
| Cardio Diagnostics Holdings, Inc. | 663.09 Thousand USD | -767.895% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 96.768% |
| Biomea Fusion, Inc. | 7.83 Million USD | 26.501% |
| PTC Therapeutics, Inc. | 284.21 Million USD | 97.975% |
| Mereo BioPharma Group plc | 5.3 Million USD | -8.585% |
| Cullinan Oncology, Inc. | 2.15 Million USD | -167.674% |
| Syndax Pharmaceuticals, Inc. | 588 Thousand USD | -878.741% |
| Absci Corporation | 4.66 Million USD | -23.498% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| 4D Molecular Therapeutics, Inc. | 11.52 Million USD | 50.052% |
| Dyne Therapeutics, Inc. | 22.69 Million USD | 74.642% |
| Kiniksa Pharmaceuticals, Ltd. | 10 Million USD | 42.479% |
| Ventyx Biosciences, Inc. | 11.5 Million USD | 49.978% |
| Allakos Inc. | 38.21 Million USD | 84.94% |
| Imunon, Inc. | 1.13 Million USD | -405.138% |
| Fulcrum Therapeutics, Inc. | 8.62 Million USD | 33.306% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| BioAtla, Inc. | 836 Thousand USD | -588.397% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -57450.0% |
| Allogene Therapeutics, Inc. | 88.34 Million USD | 93.486% |
| Larimar Therapeutics, Inc. | 4.7 Million USD | -22.213% |
| XOMA Corporation | 118.51 Million USD | 95.144% |
| Kezar Life Sciences, Inc. | 10.06 Million USD | 42.844% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 84.479% |
| aTyr Pharma, Inc. | 13.76 Million USD | 58.197% |
| Aligos Therapeutics, Inc. | 7.89 Million USD | 27.143% |
| Akero Therapeutics, Inc. | 24.96 Million USD | 76.947% |
| Viridian Therapeutics, Inc. | 20.2 Million USD | 71.517% |
| Eliem Therapeutics, Inc. | 15 Thousand USD | -38266.667% |
| EyeGate Pharmaceuticals, Inc. | 278.19 Thousand USD | -1968.73% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | 14.45 Million USD | 60.186% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.616% |
| Lexaria Bioscience Corp. | 136.17 Thousand USD | -4126.242% |
| UroGen Pharma Ltd. | 98.55 Million USD | 94.16% |
| Sutro Biopharma, Inc. | 149.11 Million USD | 96.141% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 69.817% |
| Entera Bio Ltd. | 256 Thousand USD | -2148.047% |
| GH Research PLC | 631 Thousand USD | -812.044% |
| Lisata Therapeutics, Inc. | 137.00 USD | -4200629.927% |
| Reneo Pharmaceuticals, Inc. | 642 Thousand USD | -796.417% |
| Xencor, Inc. | 14.64 Million USD | 60.695% |
| 60 Degrees Pharmaceuticals, Inc. | 150.25 Thousand USD | -3730.257% |
| Replimune Group, Inc. | 71.99 Million USD | 92.006% |
| Coeptis Therapeutics Holdings, Inc. | 150 Thousand USD | -3736.667% |
| Vanda Pharmaceuticals Inc. | 7 Million USD | 17.856% |
| Lexaria Bioscience Corp. | 136.17 Thousand USD | -4126.242% |
| Portage Biotech Inc. | 7000.00 USD | -82114.286% |
| Cardio Diagnostics Holdings, Inc. | 663.09 Thousand USD | -767.895% |
| Olema Pharmaceuticals, Inc. | 1.42 Million USD | -302.729% |
| OncoCyte Corporation | 2.2 Million USD | -161.116% |
| Qualigen Therapeutics, Inc. | - USD | -Infinity% |
| Processa Pharmaceuticals, Inc. | 66.9 Thousand USD | -8501.749% |
| Purple Biotech Ltd. | 163 Thousand USD | -3430.675% |
| CollPlant Biotechnologies Ltd. | 2.53 Million USD | -127.022% |
| scPharmaceuticals Inc. | 38.81 Million USD | 85.172% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| HilleVax, Inc. | 25.24 Million USD | 77.203% |
| NeuroSense Therapeutics Ltd. | 73 Thousand USD | -7783.562% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Neumora Therapeutics, Inc. Common Stock | 1.85 Million USD | -210.577% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | 26.34 Million USD | 78.158% |
| Curis, Inc. | 1.48 Million USD | -286.501% |
| Daré Bioscience, Inc. | 3.91 Million USD | -47.048% |
| Carmell Therapeutics Corporation | 697.71 Thousand USD | -724.835% |
| Titan Pharmaceuticals, Inc. | - USD | -Infinity% |
| Achieve Life Sciences, Inc. | 6000.00 USD | -95816.667% |
| BeiGene, Ltd. | 197.61 Million USD | 97.088% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -531.377% |
| Revolution Medicines, Inc. Warrant | 80.57 Million USD | 92.858% |
| Protagonist Therapeutics, Inc. | - USD | -Infinity% |
| Erasca, Inc. | 51.88 Million USD | 88.909% |
| bluebird bio, Inc. | 224.41 Million USD | 97.436% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 99.03% |
| DBV Technologies S.A. | 4.52 Million USD | -27.154% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Moderna, Inc. | - USD | -Infinity% |
| Vincerx Pharma, Inc. | 1.34 Million USD | -329.478% |
| Fresh Tracks Therapeutics, Inc. | - USD | -Infinity% |
| Molecular Templates, Inc. | 9.74 Million USD | 40.926% |
| Acrivon Therapeutics, Inc. Common Stock | 3.76 Million USD | -52.774% |
| Travere Therapeutics, Inc. | 377.26 Million USD | 98.475% |
| Monte Rosa Therapeutics, Inc. | 42.87 Million USD | 86.578% |
| Spruce Biosciences, Inc. | 1.71 Million USD | -235.178% |
| Celldex Therapeutics, Inc. | 928 Thousand USD | -520.151% |
| Cogent Biosciences, Inc. | 17.46 Million USD | 67.052% |
| MacroGenics, Inc. | 30.19 Million USD | 80.941% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | 17.7 Million USD | 67.491% |
| Prime Medicine, Inc. | 4.35 Million USD | -32.086% |
| Aditxt, Inc. | 1.04 Million USD | -452.439% |
| Adagene Inc. | 13.54 Million USD | 57.496% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 13.73 Million USD | 58.106% |
| Maravai LifeSciences Holdings, Inc. | 518.7 Million USD | 98.891% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 17.09 Million USD | 66.331% |
| SciSparc Ltd. | 24 Thousand USD | -23879.167% |
| Vericel Corporation | 81.85 Million USD | 92.969% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Minerva Neurosciences, Inc. | 82.01 Million USD | 92.983% |
| Generation Bio Co. | 89.77 Million USD | 93.589% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | 22.18 Million USD | 74.059% |
| Arcutis Biotherapeutics, Inc. | 201.79 Million USD | 97.148% |
| Invivyd, Inc. | 722 Thousand USD | -697.091% |
| Relay Therapeutics, Inc. | 48.5 Million USD | 88.135% |
| Quoin Pharmaceuticals, Ltd. | 2923.73 USD | -196737.601% |
| Spero Therapeutics, Inc. | 3.82 Million USD | -50.458% |
| Artelo Biosciences, Inc. | 23 Thousand USD | -24921.739% |
| 2seventy bio, Inc. | 244.01 Million USD | 97.642% |
| ADMA Biologics, Inc. | 130.59 Million USD | 95.593% |
| Clene Inc. | 7.15 Million USD | 19.533% |
| Capricor Therapeutics, Inc. | 3.37 Million USD | -70.455% |
| Boundless Bio, Inc. Common Stock | 247.61 Million USD | 97.676% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Recursion Pharmaceuticals, Inc. | 1.1 Million USD | -422.707% |
| Citius Pharmaceuticals, Inc. | 262.86 Thousand USD | -2089.337% |
| Contineum Therapeutics, Inc. Class A Common Stock | 192.62 Million USD | 97.012% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 79.738% |
| ALX Oncology Holdings Inc. | 9.63 Million USD | 40.295% |
| Vir Biotechnology, Inc. | 111.67 Million USD | 94.847% |
| Evaxion Biotech A/S | 8.48 Million USD | 32.204% |
| Ocular Therapeutix, Inc. | 74.92 Million USD | 92.319% |
| Verve Therapeutics, Inc. | 64.71 Million USD | 91.107% |
| Trevena, Inc. | 35.23 Million USD | 83.666% |
| Surrozen, Inc. | 882 Thousand USD | -552.494% |
| Tyra Biosciences, Inc. | 6.21 Million USD | 7.416% |
| Cingulate Inc. | 135.09 Thousand USD | -4159.839% |
| Galmed Pharmaceuticals Ltd. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 75.551% |
| Tenax Therapeutics, Inc. | - USD | -Infinity% |
| Terns Pharmaceuticals, Inc. | - USD | -Infinity% |
| ACADIA Pharmaceuticals Inc. | 47.8 Million USD | 87.96% |
| Connect Biopharma Holdings Limited | 180 Thousand USD | -3097.222% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Kronos Bio, Inc. | 25.37 Million USD | 77.324% |
| Bolt Biotherapeutics, Inc. | 17.43 Million USD | 66.995% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -514.85% |
| Statera Biopharma, Inc. | 11.43 Million USD | 49.655% |
| ImmunityBio, Inc. | 836.95 Million USD | 99.312% |
| Korro Bio, Inc. | 31.21 Million USD | 81.564% |
| Kineta, Inc. | 150 Thousand USD | -3736.667% |
| BioVie Inc. | 349.89 Thousand USD | -1544.784% |
| Codexis, Inc. | 12.24 Million USD | 52.994% |
| Celularity Inc. | 26.17 Million USD | 78.015% |
| Crinetics Pharmaceuticals, Inc. | 47.55 Million USD | 87.898% |
| Celcuity Inc. | 37.03 Million USD | 84.461% |
| Virax Biolabs Group Limited | 176.34 Thousand USD | -3163.489% |
| Cibus, Inc. | 17.67 Million USD | 67.438% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| IN8bio, Inc. | 3.37 Million USD | -70.317% |
| Kodiak Sciences Inc. | 100 Million USD | 94.245% |
| Annexon, Inc. | 29.19 Million USD | 80.284% |
| Adverum Biotechnologies, Inc. | 64.62 Million USD | 91.095% |
| Assembly Biosciences, Inc. | 1.12 Million USD | -412.923% |
| Avalo Therapeutics, Inc. | 2 Million USD | -187.75% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 99.589% |
| Eyenovia, Inc. | 8.95 Million USD | 35.75% |
| Puma Biotechnology, Inc. | 65.65 Million USD | 91.235% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | 8.14 Million USD | 29.317% |
| Arcellx, Inc. | 50.84 Million USD | 88.68% |
| Cardiff Oncology, Inc. | 1.45 Million USD | -294.719% |
| Enanta Pharmaceuticals, Inc. | 21.23 Million USD | 72.902% |
| Regulus Therapeutics Inc. | 1.05 Million USD | -445.498% |
| Moolec Science SA | 99.04 Thousand USD | -5710.432% |
| Acumen Pharmaceuticals, Inc. | 27.62 Million USD | 79.164% |
| Geron Corporation | 35.05 Million USD | 83.581% |
| LAVA Therapeutics N.V. | 591 Thousand USD | -873.773% |
| Royalty Pharma plc | 6.13 Billion USD | 99.906% |
| Atea Pharmaceuticals, Inc. | 1.64 Million USD | -250.487% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| TFF Pharmaceuticals, Inc. | 31.74 Thousand USD | -18030.553% |
| Mersana Therapeutics, Inc. | 23.14 Million USD | 75.138% |
| Humacyte, Inc. | 38.6 Million USD | 85.091% |
| Structure Therapeutics Inc. | 4.01 Million USD | -43.409% |
| 89bio, Inc. | 24.79 Million USD | 76.79% |
| PMV Pharmaceuticals, Inc. | 12.43 Million USD | 53.716% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | 1.86 Million USD | -208.414% |
| Trevi Therapeutics, Inc. | 1.03 Million USD | -457.655% |
| Lexicon Pharmaceuticals, Inc. | 99.5 Million USD | 94.217% |
| Notable Labs, Ltd. | 1.52 Million USD | -277.13% |
| Liquidia Corporation | 2.36 Million USD | -143.443% |
| Mustang Bio, Inc. | 1.97 Million USD | -190.95% |
| Immunovant, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 13.73 Million USD | 58.106% |
| Arbutus Biopharma Corporation | 6.95 Million USD | 17.23% |
| DiaMedica Therapeutics Inc. | 317 Thousand USD | -1715.457% |
| Vera Therapeutics, Inc. | 49.87 Million USD | 88.462% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Xenon Pharmaceuticals Inc. | 9.6 Million USD | 40.077% |
| Elevai Labs, Inc. Common Stock | 65.48 Thousand USD | -8687.735% |
| NeuroBo Pharmaceuticals, Inc. | 136 Thousand USD | -4131.618% |
| Tempest Therapeutics, Inc. | 6.26 Million USD | 8.126% |
| Soleno Therapeutics, Inc. | 130 Thousand USD | -4326.923% |
| PepGen Inc. | 17.1 Million USD | 66.345% |
| Moleculin Biotech, Inc. | 474 Thousand USD | -1114.135% |
| United Therapeutics Corporation | 300 Million USD | 98.082% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| Solid Biosciences Inc. | 23.94 Million USD | 75.962% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Immuneering Corporation | 4.16 Million USD | -38.247% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | - USD | -Infinity% |
| Belite Bio, Inc | 578 Thousand USD | -895.675% |
| XOMA Corporation | 118.51 Million USD | 95.144% |
| ARS Pharmaceuticals, Inc. | 37 Thousand USD | -15454.054% |
| Bionomics Limited | 117.62 Million USD | 95.107% |
| Apogee Therapeutics, Inc. | 933 Thousand USD | -516.827% |
| Alpha Tau Medical Ltd. | 5.61 Million USD | -2.585% |
| uniQure N.V. | 130.06 Million USD | 95.575% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 58.59 Million USD | 90.178% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | 686 Thousand USD | -738.921% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | 4.33 Million USD | -32.695% |
| FibroBiologics, Inc. Common Stock | 1.38 Million USD | -315.523% |
| Altimmune, Inc. | 175 Thousand USD | -3188.571% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 98.516% |
| Alpha Tau Medical Ltd. | 5.61 Million USD | -2.585% |
| Compugen Ltd. | 719 Thousand USD | -700.417% |
| Peak Bio, Inc. | - USD | -Infinity% |
| Zevra Therapeutics, Inc. | 5.06 Million USD | -13.6% |
| Benitec Biopharma Inc. | - USD | -Infinity% |
| Spyre Therapeutics, Inc. | 84.55 Million USD | 93.194% |
| NKGen Biotech, Inc. Common Stock | 9.93 Million USD | 42.044% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | 6.37 Million USD | 9.782% |
| Aileron Therapeutics, Inc. | 91.41 Million USD | 93.704% |
| NKGen Biotech, Inc. Warrants | 9.93 Million USD | 42.044% |
| Instil Bio, Inc. | 81.42 Million USD | 92.932% |
| argenx SE | 15.35 Million USD | 62.518% |
| Immunome, Inc. | 1.34 Million USD | -329.478% |
| Compass Therapeutics, Inc. | 536 Thousand USD | -973.694% |
| Verona Pharma plc | 48.37 Million USD | 88.103% |
| enGene Holdings Inc. Warrants | 9.21 Million USD | 37.554% |
| Shattuck Labs, Inc. | 3.4 Million USD | -68.967% |
| CervoMed Inc. | - USD | -Infinity% |
| LENZ Therapeutics, Inc. | - USD | -Infinity% |
| Plus Therapeutics, Inc. | 85 Thousand USD | -6670.588% |
| Dianthus Therapeutics, Inc. | 168 Thousand USD | -3325.595% |
| Moolec Science SA | 99.04 Thousand USD | -5710.432% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Inovio Pharmaceuticals, Inc. | 11.03 Million USD | 47.834% |
| AnaptysBio, Inc. | 16.03 Million USD | 64.114% |
| Design Therapeutics, Inc. | 2.33 Million USD | -146.572% |
| Leap Therapeutics, Inc. | - USD | -Infinity% |
| NeurAxis, Inc. | 27.07 Thousand USD | -21158.912% |
| Seelos Therapeutics, Inc. | - USD | -Infinity% |
| Lumos Pharma, Inc. | 6 Million USD | 4.083% |
| Achilles Therapeutics plc | 1.07 Million USD | -434.851% |
| enGene Holdings Inc. Common Stock | 9.21 Million USD | 37.554% |
| 180 Life Sciences Corp. | 19.93 Thousand USD | -28767.376% |
| Opiant Pharmaceuticals, Inc. | 16.74 Million USD | 65.626% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 79.82 Thousand USD | -7109.431% |
| ORIC Pharmaceuticals, Inc. | 7461.00 USD | -77034.432% |
| CG Oncology, Inc. Common stock | 13 Thousand USD | -44169.231% |
| Fractyl Health, Inc. Common Stock | 342.48 Million USD | 98.32% |
| Rani Therapeutics Holdings, Inc. | 24.48 Million USD | 76.495% |
| MoonLake Immunotherapeutics | 2.49 Million USD | -130.201% |
| Palisade Bio, Inc. | 90 Thousand USD | -6294.444% |
| Tourmaline Bio, Inc. | 194 Thousand USD | -2866.495% |
| Beam Therapeutics Inc. | 159.91 Million USD | 96.401% |
| Neurogene Inc. | 13.37 Million USD | 56.966% |
| Mirum Pharmaceuticals, Inc. | 306.42 Million USD | 98.122% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | 26.26 Million USD | 78.087% |
| Sesen Bio, Inc. | - USD | -Infinity% |
| Enliven Therapeutics, Inc. | - USD | -Infinity% |
| Kiora Pharmaceuticals, Inc. | 59.82 Thousand USD | -9520.207% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -475.5% |
| Taysha Gene Therapies, Inc. | 40.5 Million USD | 85.793% |
| Athira Pharma, Inc. | 1.21 Million USD | -372.884% |
| Vaccinex, Inc. | 26 Thousand USD | -22034.615% |
| HCW Biologics Inc. | 6.3 Million USD | 8.713% |
| XOMA Corporation | 118.51 Million USD | 95.144% |
| Nektar Therapeutics | 112.62 Million USD | 94.89% |
| Arvinas, Inc. | 800 Thousand USD | -619.375% |
| Tevogen Bio Holdings Inc. | 14.45 Million USD | 60.186% |
| Merus N.V. | 10.48 Million USD | 45.128% |
| Omega Therapeutics, Inc. | 14.88 Million USD | 61.337% |
| Quince Therapeutics, Inc. | 13.42 Million USD | 57.145% |
| Rezolute, Inc. | 1.66 Million USD | -246.687% |
| Clene Inc. | 7.15 Million USD | 19.533% |
| Indaptus Therapeutics, Inc. | 73.34 Thousand USD | -7746.158% |
| BeyondSpring Inc. | 3.36 Million USD | -71.076% |
| Synlogic, Inc. | 12.49 Million USD | 53.927% |
| Allarity Therapeutics, Inc. | - USD | -Infinity% |
| Phio Pharmaceuticals Corp. | - USD | -Infinity% |
| Peak Bio, Inc. | - USD | -Infinity% |
| Werewolf Therapeutics, Inc. | 32.65 Million USD | 82.377% |
| Krystal Biotech, Inc. | 6.62 Million USD | 13.066% |
| Karyopharm Therapeutics Inc. | 170.91 Million USD | 96.633% |
| SpringWorks Therapeutics, Inc. | 5.99 Million USD | 4.019% |
| Lipella Pharmaceuticals Inc. | 47.37 Thousand USD | -12048.783% |
| MannKind Corporation | 252.15 Million USD | 97.718% |
| Ikena Oncology, Inc. | 7.18 Million USD | 19.847% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 199 Thousand USD | -2791.96% |
| Gossamer Bio, Inc. | 197.4 Million USD | 97.085% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | 520 Thousand USD | -1006.731% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Legend Biotech Corporation | 281.32 Million USD | 97.954% |
| Mural Oncology plc | 8.91 Million USD | 35.417% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 86.842% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | 1.43 Million USD | -300.766% |
| Champions Oncology, Inc. | 6.09 Million USD | 5.547% |
| REGENXBIO Inc. | 82.22 Million USD | 93.001% |
| Ensysce Biosciences, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | 494 Thousand USD | -1064.973% |
| Edgewise Therapeutics, Inc. | 4.43 Million USD | -29.793% |
| Vaxart, Inc. | 2.62 Million USD | -119.405% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | 271.63 Thousand USD | -2018.683% |
| Cellectis S.A. | 36.24 Million USD | 84.12% |
| Longeveron Inc. | 1.44 Million USD | -297.445% |
| Repare Therapeutics Inc. | 1.01 Million USD | -469.802% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 99.492% |
| Inozyme Pharma, Inc. | 44.76 Million USD | 87.145% |
| Revolution Medicines, Inc. | 80.57 Million USD | 92.858% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | 3.2 Million USD | -79.395% |
| ArriVent BioPharma, Inc. Common Stock | 177 Thousand USD | -3151.412% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 123 Thousand USD | -4578.862% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 99.206% |
| Denali Therapeutics Inc. | 44.98 Million USD | 87.206% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 12.5 Million USD | 53.976% |
| Corvus Pharmaceuticals, Inc. | - USD | -Infinity% |
| Cingulate Inc. | 135.09 Thousand USD | -4159.839% |
| Passage Bio, Inc. | 22.92 Million USD | 74.892% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | 6.03 Million USD | 4.703% |
| Day One Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oramed Pharmaceuticals Inc. | 647 Thousand USD | -789.49% |
| Scinai Immunotherapeutics Ltd. | 20.16 Million USD | 71.46% |
| Rhythm Pharmaceuticals, Inc. | 490 Thousand USD | -1074.49% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 407.45 Thousand USD | -1312.419% |
| Carisma Therapeutics, Inc. | 1.18 Million USD | -384.428% |
| Unicycive Therapeutics, Inc. | 466 Thousand USD | -1134.979% |
| OmniAb, Inc. | 22.07 Million USD | 73.93% |
| Anew Medical, Inc. | 1.54 Million USD | -273.701% |
| Fennec Pharmaceuticals Inc. | 29.55 Million USD | 80.531% |
| Lipocine Inc. | - USD | -Infinity% |
| Lexeo Therapeutics, Inc. Common Stock | 9.03 Million USD | 36.289% |
| Nautilus Biotechnology, Inc. | 31.09 Million USD | 81.489% |
| SAB Biotherapeutics, Inc. | 4.05 Million USD | -41.949% |
| G1 Therapeutics, Inc. | 51.55 Million USD | 88.838% |
| Bellerophon Therapeutics, Inc. | - USD | -Infinity% |
| Sage Therapeutics, Inc. | - USD | -Infinity% |
| Ocugen, Inc. | 6.36 Million USD | 9.612% |
| Mind Medicine (MindMed) Inc. | 14.12 Million USD | 59.268% |
| Q32 Bio Inc. | - USD | -Infinity% |
| Brainstorm Cell Therapeutics Inc. | 672 Thousand USD | -756.399% |
| Alumis Inc. Common Stock | 30.86 Million USD | 81.351% |
| Equillium, Inc. | 384 Thousand USD | -1398.698% |
| Kyverna Therapeutics, Inc. | 6.15 Million USD | 6.56% |
| Coya Therapeutics, Inc. | - USD | -Infinity% |
| CNS Pharmaceuticals, Inc. | - USD | -Infinity% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 96.19% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 88.226% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -4683.794% |
| Dominari Holdings Inc. | 3.02 Million USD | -90.059% |
| Edesa Biotech, Inc. | 19.77 Thousand USD | -29005.346% |
| vTv Therapeutics Inc. | 169 Thousand USD | -3305.325% |
| Bio-Techne Corporation | 319 Million USD | 98.196% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 89.901% |
| Harmony Biosciences Holdings, Inc. | 178.56 Million USD | 96.777% |
| Prelude Therapeutics Incorporated | 15.4 Million USD | 62.647% |
| Candel Therapeutics, Inc. | 12.38 Million USD | 53.525% |
| iTeos Therapeutics, Inc. | 4.8 Million USD | -19.721% |
| Nkarta, Inc. | 82.27 Million USD | 93.005% |
| BioCardia, Inc. | 982 Thousand USD | -486.049% |
| Iterum Therapeutics plc | 18.95 Million USD | 69.64% |